Related Experiment Videos
Three possible laboratory indexes of disease activity in multiple sclerosis
Abstract:
In a search for an objective measure of disease activity in MS, we studied three laboratory indexes in 15 patients over 12 months, relating them to the occurrence of relapse and the development of increased disability. Relapse was associated with detection of myelin basic protein (MBP) in the CSF (p less than 0.01), but not with decreased numbers of peripheral blood T lymphocytes. Persistently low T-cell numbers and more frequent detection of MBP in remission were associated with increased disability (p less than 0.01). There were no associations between other CSF abnormalities and either relapse or increased disability.
Insights
Myelin basic protein (MBP) in cerebrospinal fluid (CSF) can indicate multiple sclerosis (MS) relapse. Persistently low T-cell counts and MBP in remission correlate with MS disease progression.
Area of Science:
- Neurology
- Immunology
- Biochemistry
Background:
- Multiple Sclerosis (MS) lacks objective measures for disease activity.
- Understanding disease markers is crucial for patient management and treatment.
Purpose of the Study:
- To identify objective laboratory markers for MS disease activity.
- To correlate laboratory findings with clinical events like relapse and disability progression.
Main Methods:
- Studied 15 MS patients over 12 months.
- Assessed three laboratory indexes, including myelin basic protein (MBP) in cerebrospinal fluid (CSF) and peripheral blood T lymphocytes.
- Related laboratory findings to relapse occurrence and increased disability.
Main Results:
- Relapse strongly correlated with MBP detection in CSF (p < 0.01).
- Peripheral blood T lymphocyte counts did not correlate with relapse.
- Persistently low T-cell numbers and MBP in remission were associated with increased disability (p < 0.01).
Conclusions:
- MBP in CSF is a potential objective marker for MS relapse.
- T-cell counts and MBP levels during remission may predict MS disability progression.
- Further research is needed to validate these markers in larger MS cohorts.